OXFORD, England, April 11, 2013 /PRNewswire/ --
PharmaVentures is pleased to announce that Techno Group Investment Holdings, a portfolio company of Gulf Capital, has acquired 100% of Doğu Tip, a Turkish provider of outsourced diagnostic imaging services, with a subsequent allocation of 25% incentive shares to the management.
PharmaVentures, a leading life science and healthcare advisory firm, was advisor to Doğu Tip and its shareholders.
Techno Group is the leading provider of diagnostic imaging services in the MENA region. Gulf Capital is a leading MENA private equity firm based in Abu Dhabi with close to $2 billion in assets under management.
PharmaVentures' CEO, Dr Fintan Walton said, "This deal marks another step in our increased success in M&A generally and in cross-border Emerging Market deals specifically. We are delighted to have worked on this transaction to deliver a successful outcome on behalf of our client".
Ping Shek, who was PharmaVentures' lead advisor on the deal said, "Turkey is a key regional hub with a large growing healthcare market. We envisage a continuing high level of investment activity there, especially since the government has recently passed new regulations encouraging foreign investment in its healthcare sector".
Established in 1992, PharmaVentures has worked on over 600 advisory assignments for clients from top global pharmaceutical and healthcare groups to fast growing biotech companies. In recent years, it has been increasingly active in M&A, working on assignments worldwide.
PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
Find out more http://www.pharmaventures.com
Our services include:
- M&A (divestments, mergers, acquisitions and strategic transactions)
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
- Licensing (in and out licensing)
- Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
For further information, contact:
Dr Fintan Walton, CEO, PharmaVentures Ltd